BioSpace News Archive

Pluristem Therapeutics Inc., a leading regenerative medicine company developing novel placenta-based cell therapy products, announced that the RESTORE Consortium is hosting its 1st Advanced Therapies Science Meeting, which is being held November 25-26, 2019 in Berlin.

Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of retina and ocular Graft-Versus-Host Disease (oGVHD) scientific advisory boards comprised of prominent experts to provide strategic advice, clinical and regulatory support, and scientific and industry expertise.

Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, announced positive interim efficacy data from the Company’s ongoing Phase Ib clinical trial in patients with severe sepsis.

Arcturus Therapeutics (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview and financial results for the quarter and nine months ended September 30, by hosting a conference call and webcast at 4:30 pm Eastern Time on Thursday, November 7, 2019.

Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2019 financial results after market close on Thursday, November 7, 2019.

Exactus, Inc. (OTCQB:EXDI) (the “Company”), a grower of hemp and producer of hemp-derived phytocannabinoid products, is pleased to announce that it has obtained several significant orders and has commenced delivery of product from its current 2019 harvest.

ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced two important milestones for the TRYbeCA1 Phase 3 clinical trial of eryaspase in second line metastatic pancreatic cancer.

The Organizations are Collaborating on Implanted Myoelectric Sensors to Control Bionic Prosthetic Limbs

Biopharmaceutical company Alvotech announced that Abu Dhabi-based investment company, Yas Holding, has acquired a 2.5% stake in their business and signed an agreement for the exclusive partnership and supply of three Alvotech biosimilar candidates, which Yas Holding will commercialize in the MENA region.

NiKang Therapeutics, an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs, announced the appointment of Y. Peter Li, Ph.D., MBA, as Chief Executive Officer and Board Director.